{"organizations": [], "uuid": "7881a156b290c491c274e76374c3f7d6e7e8c3cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-charles-river-laboratories-q4-gaap/brief-charles-river-laboratories-q4-gaap-loss-per-share-0-63-idUSASB0C5DS", "country": "US", "domain_rank": 408, "title": "Charles River Laboratories Q4 GAAP Loss Per Share $0.63", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-13T20:13:00.000+02:00", "replies_count": 0, "uuid": "7881a156b290c491c274e76374c3f7d6e7e8c3cf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-charles-river-laboratories-q4-gaap/brief-charles-river-laboratories-q4-gaap-loss-per-share-0-63-idUSASB0C5DS", "ord_in_thread": 0, "title": "Charles River Laboratories Q4 GAAP Loss Per Share $0.63", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "charles river laboratories", "sentiment": "negative"}, {"name": "reuters) - charles river laboratories international inc", "sentiment": "neutral"}, {"name": "mpi", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Charles River Laboratories International Inc:\n* CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS FROM CONTINUING OPERATIONS AND PROVIDES 2018 GUIDANCE\n* Q4 NON-GAAP EARNINGS PER SHARE $1.40\n* Q4 GAAP LOSS PER SHARE $0.63 * Q4 REVENUE ROSE 2.5 PERCENT TO $478.5 MILLION * Q4 EARNINGS PER SHARE VIEW $1.25, REVENUE VIEW $474.6 MILLION -- THOMSON REUTERS I/B/E/S\n* CHARLES RIVER LABORATORIES SEES 2018 NON-GAAP EARNINGS PER SHARE FROM CONTINUING OPERATIONS $5.42 - $5.57\n* CHARLES RIVER LABORATORIES SEES 2018 GAAP EARNINGS PER SHARE FROM CONTINUING OPERATIONS $4.71 - $4.86\n* SEES 2018 REVENUE GROWTH, REPORTED, FROM CONTINUING OPERATIONS OF 7.2% TO 8.2%\n* FY2018 EARNINGS PER SHARE VIEW $5.58, REVENUE VIEW $1.99 BILLION -- THOMSON REUTERS I/B/E/S\n* CHARLES RIVER LABORATORIES - EXCLUDING MPI, 2018 EPS EXPECTED TO BENEFIT FROM HIGHER REVENUE, MODEST OPERATING. MARGIN IMPROVEMENT\n* CHARLES RIVER LABORATORIES - 2018 EARNINGS PER SHARE GUIDANCE INCLUDES GAIN OF $0.14 ON VENTURE CAPITAL INVESTMENTS\n* CHARLES RIVER LABORATORIES - 2018 EARNINGS PER SHARE GUIDANCE ALSO INCLUDES GAIN OF $0.14 FOR EXCESS TAX BENEFIT ASSOCIATED WITH STOCK COMPENSATION\n* CHARLES RIVER LABORATORIES SEES 2018 NON-GAAP EARNINGS PER SHARE INCLUDING MPI $5.67 - $5.82 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T20:13:00.000+02:00", "crawled": "2018-02-14T12:13:16.000+02:00", "highlightTitle": ""}